Immunotherapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma) that cannot be treated with surgery or local treatments like chemoembolization.
- You are about to start your first systemic treatment (treatment that goes through your whole body) with atezolizumab and bevacizumab or another immunotherapy.
- You are not currently receiving any other cancer medications.
- You do not have another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
This study looks at how well immunotherapy combinations work as the first treatment for advanced liver cancer that can't be surgically removed. It will track real-world patients to see how safe and effective these treatments are.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer in real life, outside of a clinical trial. It will help doctors understand the treatment's benefits and risks based on patient records.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial is testing how well immune checkpoint inhibitors, which help the body's immune system fight cancer, work in people with advanced liver cancer. The goal is to see if these drugs are effective and safe for patients whose liver is still working reasonably well.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.